A method of inhibiting growth of cancerous cells involves contacting the cancerous cells with a very long chain fatty acid elongase 6 inhibitor (ELOVL6i). The cancerous cells are KRAS dependent. The ELOVL6i reduces a level of KRAS expressed by the cancerous cells, relative to a level thereof prior to contacting of the ELOVL6i, thereby inhibiting the growth of the cancerous cells.